 Connection
Robert Belknap to Tuberculosis
This is a "connection" page, showing publications Robert Belknap has written about Tuberculosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
4.245 |
|
|
|
-
Flynn AG, Aiona K, Haas MK, Reves R, Belknap R. Clinical Characteristics of Active Tuberculosis Diagnosed After Starting Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2020 08 22; 71(5):1320-1323.
Score: 0.506
-
Sosa LE, Njie GJ, Lobato MN, Bamrah Morris S, Buchta W, Casey ML, Goswami ND, Gruden M, Hurst BJ, Khan AR, Kuhar DT, Lewinsohn DM, Mathew TA, Mazurek GH, Reves R, Paulos L, Thanassi W, Will L, Belknap R. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR Morb Mortal Wkly Rep. 2019 May 17; 68(19):439-443.
Score: 0.463
-
Belknap R, Reves R. In reply: We and our patients must demand better TB diagnostics. Int J Tuberc Lung Dis. 2017 12 01; 21(12):1316.
Score: 0.419
-
Chaulk CP, Belknap R. A public heath 'selfie' for treating tuberculosis? Int J Tuberc Lung Dis. 2016 May; 20(5):571.
Score: 0.375
-
Collins JM, Reves RR, Belknap RW. High Rates of Tuberculosis and Opportunities for Prevention among International Students in the United States. Ann Am Thorac Soc. 2016 Apr; 13(4):522-8.
Score: 0.373
-
Belknap R, Daley CL. Interferon-gamma release assays. Clin Lab Med. 2014 Jun; 34(2):337-49.
Score: 0.325
-
Gray J, Reves R, Johnson S, Belknap R. Identification of false-positive QuantiFERON-TB Gold In-Tube assays by repeat testing in HIV-infected patients at low risk for tuberculosis. Clin Infect Dis. 2012 Feb 01; 54(3):e20-3.
Score: 0.275
-
Belknap R, Wall K, Reves R. What can the NHANES data tell us about the tuberculin skin test and the risk for active tuberculosis? Am J Respir Crit Care Med. 2008 Oct 15; 178(8):883-4; author reply 884.
Score: 0.222
-
Ayers T, Hill AN, Raykin J, Mohanty S, Belknap RW, Brostrom R, Khurana R, Lauzardo M, Miller TL, Narita M, Pettit AC, Pyan A, Salcedo KL, Polony A, Flood J. Comparison of Tuberculin Skin Testing and Interferon-? Release Assays in Predicting Tuberculosis Disease. JAMA Netw Open. 2024 04 01; 7(4):e244769.
Score: 0.162
-
Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, Kunihira Tinka L, Nakimuli J, Ritar Kasidi J, Bishop O, Nakasendwa S, Baik Y, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PP, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial. PLoS Med. 2024 02; 21(2):e1004356.
Score: 0.161
-
Zavala S, Winglee K, Ho CS, Pettit AC, Ahmed A, Katz DJ, Belknap RW, Stout JE. Examining Test Cutoffs to Optimize Diagnosis of Latent Tuberculosis Infection in People Born Outside the United States. Ann Am Thorac Soc. 2023 09; 20(9):1258-1266.
Score: 0.156
-
Winters N, Belknap R, Benedetti A, Borisov A, Campbell JR, Chaisson RE, Chan PC, Martinson N, Nahid P, Scott NA, Sizemore E, Sterling TR, Villarino ME, Wang JY, Menzies D. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Lancet Respir Med. 2023 09; 11(9):782-790.
Score: 0.151
-
Winglee K, Hill AN, Belknap R, Stout JE, Ayers TL. Variability of interferon-? release assays in people at high risk of tuberculosis infection or progression to tuberculosis disease living in the United States. Clin Microbiol Infect. 2022 Jul; 28(7):1023.e1-1023.e7.
Score: 0.140
-
Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS Med. 2021 12; 18(12):e1003875.
Score: 0.139
-
Feng PJ, Wu Y, Ho CS, Chinna L, Whelen AC, Largen A, Brostrom R, Reves R, Belknap R, Cattamanchi A, Banaei N. Impact of T-Cell Xtend on T-SPOT.TB Assay in High-Risk Individuals after Delayed Blood Sample Processing. J Clin Microbiol. 2021 04 20; 59(5).
Score: 0.132
-
Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba A, Dowdy D, Semitala FC, Cattamanchi A. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implement Sci. 2020 08 12; 15(1):65.
Score: 0.126
-
Venkatappa TK, Punnoose R, Katz DJ, Higgins MP, Banaei N, Graviss EA, Belknap RW, Ho CS. Comparing QuantiFERON-TB Gold Plus with Other Tests To Diagnose Mycobacterium tuberculosis Infection. J Clin Microbiol. 2019 11; 57(11).
Score: 0.119
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|